However, the associations with lymph node metastasis, tumor size, and histopathological grade were not significant in their analysis. Recently, a prospective study (n=69) by Budiana et al. also found higher median CRP/Alb levels in advanced-stage ovarian cancer patients (11.0 vs 1.92; p=0.000), calculating a cutoff of 1.34 for diagnosing advanced-stage cancer (sensitivity 86.9%, specificity 68%) [20]. This evidence concerns the gene CRP and ovarian carcinoma.